-
Mashup Score: 12Education sets the basis for an AI-driven future of oncology - 11 day(s) ago
The deployment of AI could lead to substantial advances in cancer care, but collaborative efforts are needed to increase trust among end users
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 10Redispensing cancer medicines means caring for the environment - 24 day(s) ago
Collection and distribution of unused medicines can help tackle drug waste, with a potential impact on emissions associated to oncology therapies
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Redispensing #CancerMedications is a way to care for the environment. Some initiatives show that the collection & distribution of unused medications can help address #DrugWaste, potentially reducing emissions linked to #OncologyTherapies.#ESMODailyReporter https://t.co/BkKfBdUAig https://t.co/RGTgA82GRT
-
-
Mashup Score: 12Translating cancer genome insights into practical clinical tools - 1 month(s) ago
Complex statistical modelling can form the basis for easy-to-use precision diagnostic and risk-stratification tools to help management decisions
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
#MAP2024: Findings from complex statistical modelling can form the basis for easy-to-use precision diagnostic and risk-stratification tools to help inform management decisions. @PapaemmanuilLab #ESMODailyReporter 📌https://t.co/1xi8qP8eie https://t.co/GoZfGp80Zh
-
-
Mashup Score: 8Application of sequencing techniques for cancer treatment - 1 month(s) ago
Whole-genome sequencing and single-cell sequencing provide valuable insights also to assess minimal residual disease & overcome treatment resistance
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Studies at #MAP2024 show that whole-genome sequencing and single-cell sequencing provide insights for identifying new therapy targets, assessing minimal residual disease, and overcoming treatment resistance. #ESMODailyReporter 📌https://t.co/63bx8FR7N9 https://t.co/HZZ83gKlQo
-
-
Mashup Score: 24Liquid biopsies are quickly evolving beyond ctDNA - 1 month(s) ago
Newly-presented studies highlight that insights into cancer can also be unlocked from circulating tumour cells, exosomal microRNA and cell-free RNA
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Three studies at #MAP2024 show that analysing CTCs, exo-miRNA, and cfRNA from plasma samples can improve cancer progression prediction and early detection, expanding the potential of #LiquidBiopsy beyond #ctDNA analysis. @NicolaFuscoMD #ESMODailyReporter https://t.co/L4PKPIWkeF https://t.co/GApdO2o9zf
-
-
Mashup Score: 10Data from molecular analyses unveil diverse resistance mechanisms - 1 month(s) ago
Among the presented findings, a potential role for ESR1 gene fusions was observed
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
New insights into endocrine therapy resistance mechanisms in #BreastCancer were presented at #MAP2024, unveiling a potential role of ESR1 gene fusions and providing important information for guiding treatment. #ESMODailyReporter 📌https://t.co/q1H7WGyGtN https://t.co/l2FaPTFgR1
-
-
Mashup Score: 12Innovation is leading to a comprehensive ‘map’ of tumours - 1 month(s) ago
Advances in spatial transcriptomics could provide novel opportunities for early detection, metastasis prediction and identification of actionable targ
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
#MAP2024: Advances in spatial transcriptomics could provide novel opportunities for early detection, metastasis prediction and identification of actionable targets. @JoakimLundeberg #ESMODailyReporter 📌https://t.co/bPa8PAKQrT https://t.co/He8WyU5KCa
-
-
Mashup Score: 8Adjuvant immunotherapy confirms its efficacy in melanoma - 1 month(s) ago
Updated data from two studies report significant improvements in RFS and DMFS with pembrolizumab or nivolumab
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
At #ESMO24, updated data of KEYNOTE-716 and CheckMate 76K studies confirm the key role of anti-programmed cell death protein 1 (PD-1)-based immunotherapy in the adjuvant setting for patients with #melanoma. #ESMODailyReporter 📌https://t.co/yQ47iGzvIT https://t.co/v1JxDajozl
-
-
Mashup Score: 6The expanding toolbox for immuno-oncology - 1 month(s) ago
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Immunotherapy in oncology is a challenge.@ElenaGarralda's latest column in #ESMODailyReporter explores the expanding toolbox for immuno-oncology, and how early-phase clinical trials at #ESMO24 showed promising anti-tumour effects in advanced #SolidTumours. https://t.co/R1A4ISAy4B https://t.co/jNa48F69MC
-
-
Mashup Score: 3A c-Met directed ADC shows preliminary activity in a NSCLC cohort - 2 month(s) ago
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
Source: dailyreporter.esmo.orgCategories: General Medicine News, Oncologists1Tweet-
Antitumour activity of telisotuzumab adizutecan (ABBV-400), a c-Met directed antibody-drug conjugate (ADC), was observed in previously treated patients w/ EGFR Wild Type non-squamous #NSCLC. #ESMO24 #ESMODailyReporter 👉https://t.co/uLsRBrfHEk https://t.co/OMgyVHCkO0
-
Education sets the basis for an AI-driven future in oncology. The deployment of #AI could lead to substantial advances in #CancerCare, but collaborative efforts are needed to increase trust among end users. @mireiacrispin #ESMODailyReporter👉 https://t.co/R90Gp4t1pU https://t.co/vs7jr5cKth